Ku ya 16 Werurwe 2025, Akeso yatangaje ko umuti wayo mushya wo kurwanya kanseri ya monoclonal anti-PD-1 wikora, penpulimab, wemejwe ku mugaragaro n’Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) kugira ngo uvurwe kanseri yo mu nda isubira cyangwa ihinduka (NPC) hamwe na chimiotherapie.
Penpulimab (PD-1 Monoclonal Antibody) ubu ni yo antibody yonyine ya PD-1 monoclonal ikoresha ubwoko bwa IgG1 hamwe na Fc-nulldomain yahinduwe, ishobora kongera neza imikorere y’ubudahangarwa bw’umubiri no kugabanya ingaruka mbi ziterwa n’ubudahangarwa bw’umubiri. Ikoreshwa mu kuvura indwara zikomeye nka kanseri y’ibihaha, kanseri ya lymphoma, kanseri yo mu nda, kanseri y’umwijima, na kanseri y’igifu, hamwe n’umutekano n’ubushobozi bwiza nk’uko byagaragajwe mu bushakashatsi bwa muganga.
Iki ni ikimenyetso cya kane cyemewe cya penpulimab. Uretse ibimenyetso bibiri bya NPC, penpulimab yemewe kandi ku rwego rwa mbere kuvura kanseri y’ibihaha iteye imbere cyangwa itera kanseri y’ibihaha (NSCLC) iyo ihujwe na chemotherapy, ndetse no kuvura abarwayi bafite kanseri ya Hodgkin lymphoma (cHL) yasubiwemo cyangwa itarakira mbere, bakaba barahawe nibura imirongo ibiri ya chemotherapy. Byongeye kandi, hari isuzumwa ry’inyongera rya New Drug Application (sNDA) kuri penpulimab hamwe na anlotinib mu rwego rwa mbere kuvura kanseri y’umwijima (HCC) iteye imbere.
Mbere, penpulimab yari yemewe gukoreshwa nk'ubuvuzi bwo ku rwego rwa gatatu kuri NPC iteye imbere. Hamwe n'ubu buryo bushya bwo kwemererwa, penpulimab ubu itanga ubuvuzi bwuzuye mu byiciro byose bya NPC, iha abarwayi uburyo buhoraho bwo kuvura ubudahangarwa bw'umubiri kuva ku rwego rwa mbere kugeza ku rwego rwa gatatu.
Ku ya 19 Kamena 2024, “Signal Transduction and Targeted Therapy” yasohoye ibyavuye mu bushakashatsi bwakozwe mu cyiciro cya kabiri ku kuvura kanseri yo mu nda yavuwe mbere hakoreshejwe pembrolizumab.
Iri gerageza ryakozwe mu cyiciro cya kabiri cy’igerageza ryakozwe mu bigo 20 by’ubuvuzi mu Bushinwa ryigaga abarwayi bakuru bafite kanseri yo mu nda (NPC) yangiritse, bari barananiwe gufata imiti ibiri cyangwa irenga ya kanseri y’umubiri. Abarwayi bahawe penpulimab 200 mg mu mitsi buri byumweru 2 (ibyumweru 4 kuri buri ruziga) kugeza igihe indwara ikomeje cyangwa uburozi budashobora kwihanganirwa. Ishingiro ry’ibanze ryari igipimo cy’ubutabazi bw’ibanze (ORR) kuri buri RECIST (version 1.1), nk’uko byagenzuwe na komite yigenga isuzuma ry’imirasire. Ishingiro ry’inshuro ebyiri ryarimo kubaho nta guhindagurika (PFS) no kubaho muri rusange (OS). Abarwayi 130 biyandikishije kandi 125 barasuzumwe. Ku itariki yo gusoza amakuru (ku ya 28 Nzeri 2022), umurwayi 1 yasubijwe neza naho abarwayi 34 basubijwe igice. ORR yari 28.0% (95% CI 20.3–36.7%). Igisubizo cyari kirambye, aho 66.8% bagisubije nyuma y’amezi 9. Abarwayi 33 (26.4%) bari bakiri ku miti. Impuzandengo ya PFS na OS yari amezi 3.6 (95% CI = amezi 1.9–7.3) n'amezi 22.8 (95% CI = amezi 17.1 kugeza ubu), uko bikurikirana. Abarwayi icumi (7.6%) bahuye n'imyanya ya 3 cyangwa irenga ya irAE. Penpulimab ifite ibikorwa byiza byo kurwanya ikibyimba n'uburozi bwemewe ku barwayi ba NPC bavuwe mbere y'uko bavurwa, bifasha iterambere ry'ubuvuzi nk'uburyo bwa gatatu bwo kuvura NPC ya metastatic.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Igihe cyo kohereza: 25 Mata 2025